For the first time, a cellular therapy for Parkinson's has cleared a regulatory hurdle.
Por décadas, os mais de dez milhões de pessoas diagnosticadas com Parkinson no mundo receberam tratamentos que aliviavam os sintomas, mas nunca tocavam na raiz do problema. Agora, o Japão aprovou pela primeira vez uma terapia baseada em células-tronco reprogramadas para restaurar os neurônios produtores de dopamina destruídos pela doença — não apenas administrar suas consequências. É um momento raro na medicina: quando a ciência deixa de negociar com uma doença e começa, com cautela, a enfrentá-la em seus fundamentos.
- O Parkinson destrói progressivamente os neurônios que controlam movimento, fala e equilíbrio, e os tratamentos existentes há décadas nunca conseguiram deter esse processo — apenas suavizá-lo.
- O Japão concedeu aprovação condicional à primeira terapia celular para Parkinson, um marco regulatório inédito que sinaliza uma virada na abordagem científica da doença.
- Sete pacientes receberam o tratamento e apresentaram melhora nos tremores, mas tentativas anteriores falharam — inclusive uma no Canadá em que as células transplantadas se reproduziram de forma descontrolada.
- A BlueRock Therapeutics avança em paralelo com uma abordagem que usa neurônios já maduros no momento do transplante, eliminando o risco de crescimento descontrolado, e está na fase três de ensaios clínicos.
- Os dados preliminares sugerem efeito durável de pelo menos três anos, mas pesquisadores ainda precisam confirmar se a terapia realmente desacelera a progressão da doença ou apenas gerencia sintomas.
Mais de dez milhões de pessoas vivem com Parkinson no mundo. Por décadas, a medicina ofereceu a elas medicamentos e procedimentos cirúrgicos capazes de amenizar tremores e rigidez — mas sempre em uma batalha perdida contra o avanço da própria doença. Este ano, o Japão aprovou algo diferente: uma terapia construída a partir de células-tronco reprogramadas, a primeira tentativa real de desacelerar, ou talvez interromper, o declínio neurológico que até agora parecia inevitável.
O princípio é direto. O Parkinson destrói os neurônios produtores de dopamina no cérebro — células responsáveis pelos sinais que nos permitem mover, falar, escrever. A nova terapia transforma células-tronco em laboratório nesses neurônios e os transplanta no cérebro, onde podem, em teoria, restaurar o que a doença destruiu. Sete pacientes foram tratados até agora, com resultados encorajadores o suficiente para que o Japão concedesse aprovação condicional, com monitoramento previsto por sete anos.
O neurologista Rubens Cury, do Hospital Israelita Einstein em São Paulo, destaca o peso do momento: abordagens com células-tronco para Parkinson já foram tentadas antes e falharam. Um ensaio anterior no Canadá terminou em desastre, com as células transplantadas se reproduzindo sem controle. Desta vez, algo funcionou. Ainda assim, resta confirmar se a terapia realmente desacelera a progressão da doença ou apenas administra seus sintomas.
Em paralelo, a BlueRock Therapeutics — adquirida pela Bayer em 2019 — desenvolve uma estratégia semelhante com uma diferença crucial: as células já chegam ao cérebro como neurônios maduros, incapazes de se replicar, eliminando o risco que comprometeu tentativas anteriores. A empresa está na fase três de ensaios clínicos, e os dados acumulados sugerem efeito durável de pelo menos três anos, com boa relação entre segurança e eficácia.
Desde a chegada da levodopa, há quase um século, o tratamento padrão do Parkinson nunca mudou de natureza: repor dopamina, gerenciar consequências. As novas terapias celulares propõem algo diferente — restaurar a maquinaria biológica perdida. Os ensaios são pequenos, a aprovação é condicional, e o horizonte se mede em anos. Mas para milhões de pessoas que convivem com tremores progressivos e perda gradual do controle sobre o próprio corpo, essa possibilidade oferece algo que escasseou por muito tempo no tratamento do Parkinson: esperança genuína.
More than ten million people around the world carry a Parkinson's diagnosis. For decades, medicine has offered them drugs and surgical procedures that can soften the blow—dulling tremors, easing the stiffness that makes walking difficult, reducing the pain that accumulates as the disease tightens its grip. But these treatments have always fought a losing battle against the underlying machinery of the illness itself. This year, Japan approved something different: a therapy built from reprogrammed stem cells that represents the first real attempt to slow, or possibly halt, the neurological decline that has until now seemed inevitable.
The treatment works on a simple principle. Parkinson's disease destroys dopamine-producing neurons in the brain—cells responsible for the signals that let us move, speak, eat, write. Without them, the body gradually loses its ability to do these things. The new therapy takes stem cells and transforms them in the laboratory into neurons capable of producing dopamine, then transplants them into the brain where they can theoretically restore what the disease has taken away. Seven patients have received the treatment so far, and the results have been encouraging enough that Japan granted conditional approval, with the understanding that researchers will continue monitoring these patients for the next seven years to confirm safety and sustained benefit.
Rubens Cury, a neurologist at Einstein Hospital Israelita in São Paulo, emphasizes what makes this moment significant. Stem cell approaches for Parkinson's have been attempted before, he notes, but they have failed. A previous trial in Canada saw the transplanted cells reproduce uncontrollably, turning a treatment into a threat. This time, something worked. The patients improved. Tremors diminished. The technique still needs refinement, and the long-term picture remains uncertain—researchers must determine whether the therapy can genuinely slow disease progression or merely manage symptoms. But for the first time, a cellular therapy for Parkinson's has cleared a regulatory hurdle.
A second approach is moving through the pipeline in parallel. BlueRock Therapeutics, acquired by Bayer in 2019, is developing a similar strategy: stem cells adapted in the laboratory to become dopamine-producing neurons. The critical difference is timing. By the time these cells reach the brain, they are already transformed into mature neurons, no longer capable of replicating—a safeguard against the runaway growth that derailed earlier attempts. The company is now in phase three of clinical trials, the final stage before seeking regulatory approval. Gabriel Belfort, vice-president of BlueRock Therapeutics, reports that patients will be monitored for five years following surgery. The data collected so far, across earlier trial phases, suggests a durable effect lasting at least three years, with a favorable balance of safety and efficacy.
The approval in Japan marks a watershed. For nearly a century, the standard treatment for Parkinson's has been levodopa, a drug that replenishes dopamine in the brain and eases motor symptoms. It was revolutionary when it arrived. But it has always been a substitute, not a cure—a way to manage what the disease does rather than stop it from doing it. The new cellular therapies represent a different ambition: to replace what is lost, to restore the biological machinery itself. The trials are small, the approval conditional, the timeline measured in years. But for millions of people living with progressive tremors, stiffness, and the creeping loss of control over their own bodies, the possibility that science might finally address the root cause rather than merely its symptoms offers something that has been scarce in Parkinson's treatment for a very long time: genuine hope.
Notable Quotes
The patients improved, but researchers will continue refining the technique and monitoring safety. This is the first time a stem cell therapy for Parkinson's has actually worked.— Rubens Cury, neurologist at Einstein Hospital Israelita, São Paulo
Data from earlier phases suggests a durable effect lasting at least three years, with a favorable balance of safety and efficacy.— Gabriel Belfort, vice-president of BlueRock Therapeutics
The Hearth Conversation Another angle on the story
Why does dopamine matter so much in Parkinson's? It seems like just one chemical among many in the brain.
It is just one chemical, but it's the one that orchestrates movement. Without it, your brain can't send the signals that tell your muscles what to do. Parkinson's systematically destroys the neurons that make it. So you lose the ability to move smoothly, to speak clearly, to feed yourself. The disease doesn't just take away motion—it takes away autonomy.
And the stem cell approach is trying to replace those neurons?
Exactly. Instead of giving patients a drug that mimics dopamine, you're putting new cells in the brain that can actually produce it. It's the difference between a prosthetic and a restored limb.
But the earlier trial in Canada failed because the cells kept multiplying. How did they solve that?
They matured the cells completely before transplanting them. Once they're fully transformed into neurons, they stop dividing. It's like the difference between planting a seed and planting a fully grown tree. The seed might take over the garden. The tree just stands there and does its job.
Seven patients is a very small number. How confident should we be in these results?
Cautiously. The tremors did reduce, which is real. But we don't know yet if this slows the disease itself or just manages symptoms better than current drugs. That's why the approval is conditional—they're going to watch these seven patients for seven years. It's a proof of concept, not a cure announcement.
What happens to the patients who don't respond?
That's the harder question. This first approval targets people whose disease has resisted standard medications. For them, this is a chance. For everyone else, we're still waiting for the next phase of trials to show whether it works more broadly.